Oruka Therapeutics, Inc.: operating expenses
Operating expenses for Oruka Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Oruka Therapeutics, Inc. financial histories
What this measure means
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
Exact concept: us-gaap:OperatingExpenses. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2010-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 122,051,000 | USD | 2026-03-12 | 10-K · 0001213900-26-026929 |
| 2024-02-06 | 2024-12-31 | 88,123,000 | USD | 2026-03-12 | 10-K · 0001213900-26-026929 |
| 2023-01-01 | 2023-12-31 | 7,296,000 | USD | 2024-02-01 | 10-K · 0000950170-24-009809 |
| 2022-01-01 | 2022-12-31 | 10,596,000 | USD | 2024-02-01 | 10-K · 0000950170-24-009809 |
| 2021-01-01 | 2021-12-31 | 19,335,000 | USD | 2023-02-24 | 10-K · 0000950170-23-004379 |
| 2020-01-01 | 2020-12-31 | 9,766,000 | USD | 2022-03-14 | 10-K · 0001564590-22-010075 |
| 2019-01-01 | 2019-12-31 | 5,814,000 | USD | 2021-03-18 | 10-K · 0001564590-21-014148 |
| 2018-01-01 | 2018-12-31 | 8,118,000 | USD | 2020-02-18 | 10-K · 0001564590-20-005032 |
| 2017-01-01 | 2017-12-31 | 18,712,000 | USD | 2019-02-27 | 10-K · 0001564590-19-004882 |
| 2016-01-01 | 2016-12-31 | 16,613,000 | USD | 2018-03-22 | 10-K · 0001564590-18-006566 |
| 2015-01-01 | 2015-12-31 | 11,455,000 | USD | 2017-03-21 | 10-K · 0001564590-17-004897 |
| 2014-01-01 | 2014-12-31 | 9,693,000 | USD | 2016-03-17 | 10-K · 0001564590-16-014989 |
| 2013-01-01 | 2013-12-31 | 6,940,000 | USD | 2014-03-20 | 10-K · 0001564590-14-000934 |
| 2012-01-01 | 2012-12-31 | 4,319,000 | USD | 2014-03-20 | 10-K · 0001564590-14-000934 |
| 2011-01-01 | 2011-12-31 | 7,361,000 | USD | 2013-03-21 | 10-K · 0001193125-13-119763 |
| 2010-01-01 | 2010-12-31 | 9,175,000 | USD | 2012-03-27 | 10-K · 0001193125-12-134451 |
Related financial histories
- Oruka Therapeutics, Inc.: total assets
- Oruka Therapeutics, Inc.: total liabilities
- Oruka Therapeutics, Inc.: stockholders equity
- Oruka Therapeutics, Inc.: cash and cash equivalents
- Oruka Therapeutics, Inc.: net income or loss
- Oruka Therapeutics, Inc.: operating cash flow
- Oruka Therapeutics, Inc.: capital expenditure payments
- Oruka Therapeutics, Inc.: revenue
- Oruka Therapeutics, Inc.: financing cash flow
- Oruka Therapeutics, Inc.: investing cash flow
- Oruka Therapeutics, Inc.: retained earnings or deficit
- Oruka Therapeutics, Inc.: basic weighted-average shares
- Oruka Therapeutics, Inc.: diluted weighted-average shares
- Oruka Therapeutics, Inc.: basic earnings per share
- Oruka Therapeutics, Inc.: diluted earnings per share
- Oruka Therapeutics, Inc.: income tax expense or benefit
- Oruka Therapeutics, Inc.: net property, plant and equipment
- Oruka Therapeutics, Inc.: share-based compensation expense
- Oruka Therapeutics, Inc.: operating income or loss
- Oruka Therapeutics, Inc.: current assets
- Oruka Therapeutics, Inc.: interest expense
- Oruka Therapeutics, Inc.: current liabilities
- Oruka Therapeutics, Inc.: current accounts payable
- Oruka Therapeutics, Inc.: selling, general and administrative expense
- Oruka Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Oruka Therapeutics, Inc. / CIK 0000907654
- Captured
- 2026-09-20T05:05:43.293Z
- SEC response SHA-256
3e23b48bd43d48690cc2da8767bd994ea7ae37e724c61a9cefa6f2950dc21518
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000907654.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))